Summary
Menopause can have extremely negative consequences on the quality of life, health, & work productivity of women due to the symptoms they experience. Every woman goes through menopause (~440m globally) but the transition to this point, known as perimenopause, can last 5-10 yrs. There are up to 35 symptoms of perimenopause that affect women and 75% report moderate to-severe symptoms that interfere with their life (330m women). There are no blood tests to diagnose perimenopause and treatment depends on the symptom profile but there are no objective ways to detect the symptoms, quantify their frequency & severity or track changes in profiles over time. Clinicians spend most of their time validating the self-reported information from women and of the 60% of women that seek help for their perimenopausal symptoms, 70% remain untreated. The gap in the market is the availability of objective symptom data that can (i) provide women with information they need about their perimenopausal symptoms, (ii) be shared with their clinicians to get an earlier and more accurate diagnosis. Our innovation is a novel, first-of-its-kind, product to objectively detect and track menopausal symptoms. We have developed a technology enabled AI platform using a biosensor patch that sits under the breast on the left-hand that can detect the frequency & severity of perimenopausal symptoms. Our objectives, in line with the expected impact of the Women TechEU programme, are (i) to build a digital platform, allowing us to demonstrate a D2C product for perimenopausal symptom detection, (ii) to use the mentoring & training sessions to prepare a market entry strategy for a D2C product.; (iii) to de-risk private equity investment in a female led, Femtech company by having a demonstrable product. We have an experienced, gender-balanced, team made up of leading product development, clinical, software development & commercialisation experts, with a track record of delivering projects on time and in budget.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101114304 |
| Start date: | 01-07-2023 |
| End date: | 31-01-2024 |
| Total budget - Public funding: | - 75 000,00 Euro |
Cordis data
Original description
Menopause can have extremely negative consequences on the quality of life, health, & work productivity of women due to the symptoms they experience. Every woman goes through menopause (~440m globally) but the transition to this point, known as perimenopause, can last 5-10 yrs. There are up to 35 symptoms of perimenopause that affect women and 75% report moderate to-severe symptoms that interfere with their life (330m women). There are no blood tests to diagnose perimenopause and treatment depends on the symptom profile but there are no objective ways to detect the symptoms, quantify their frequency & severity or track changes in profiles over time. Clinicians spend most of their time validating the self-reported information from women and of the 60% of women that seek help for their perimenopausal symptoms, 70% remain untreated. The gap in the market is the availability of objective symptom data that can (i) provide women with information they need about their perimenopausal symptoms, (ii) be shared with their clinicians to get an earlier and more accurate diagnosis. Our innovation is a novel, first-of-its-kind, product to objectively detect and track menopausal symptoms. We have developed a technology enabled AI platform using a biosensor patch that sits under the breast on the left-hand that can detect the frequency & severity of perimenopausal symptoms. Our objectives, in line with the expected impact of the Women TechEU programme, are (i) to build a digital platform, allowing us to demonstrate a D2C product for perimenopausal symptom detection, (ii) to use the mentoring & training sessions to prepare a market entry strategy for a D2C product.; (iii) to de-risk private equity investment in a female led, Femtech company by having a demonstrable product. We have an experienced, gender-balanced, team made up of leading product development, clinical, software development & commercialisation experts, with a track record of delivering projects on time and in budget.Status
SIGNEDCall topic
HORIZON-EIE-2022-SCALEUP-02-02Update Date
31-07-2023
Images
No images available.
Geographical location(s)
